

Supplementary Table 9: Details of included studies: radiotherapy

Study (year) - Design	Population (n)	Prior therapy (n)	Radiotherapy (n)	Mean duration of follow-up in years (range)	Outcome			Adverse events (n)
					Radiological response (n)	Biochemical response (n)	Survival	
Burman (2022) - Cohort	APT (121) - somatotroph (12) - lactotroph (38) - corticotroph (32) - NFPA (33) - thyreotroph (3) - gonadotroph (1) - unknown (2) PC (50) - somatotroph (3) - lactotroph (16) - corticotroph (19) - nonfunctioning (12) A second course of radiotherapy was given to 55/171 patients (32.2%)	n.r.	Second course (55): Single dose (19)	n.r.	CR [◇] 3.2% (2) PR [◇] 42.1% (23) SD [◇] 47.4% (26) PD [◇] 7.3% (4)	-	-	n.r.
APT = aggressive pituitary tumour PC = pituitary carcinoma NFPA = nonfunctioning pituitary adenoma LINAC = linear accelerator n.r. = not reported ◇ According to the following criteria: CR = complete response: disappearance of all lesions PR = partial response: ≥ 30% reduction in tumour volume SD = stable disease: change in tumour volume between ≤ 30% decrease and ≤ 10% increase from baseline PD = progressive disease: ≥ 10% increase in tumour volume								